The Global Fluorodeoxyglucose Market was valued at USD 34 Million in 2023 and is projected to reach USD 47.56 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 3.80% during the forecast period (2023–2032). This growth is being driven by the rising prevalence of cancer and neurological disorders, increasing demand for advanced diagnostic imaging, and the expanding adoption of positron emission tomography (PET) scans in clinical settings worldwide.
As the medical imaging sector evolves toward more precise and non-invasive diagnostics, the focus turns to the leading producers of radiopharmaceuticals who are pioneering innovations in tracer technology, production efficiency, and regulatory compliance. In this blog, we profile the Top 10 Companies in the Fluorodeoxyglucose Market—a blend of global healthcare giants, specialized radiopharma firms, and emerging innovators shaping the future of diagnostic radiology.
🔟 1. GE Healthcare
Headquarters: Chicago, Illinois, USA
Key Offering: FDG for PET imaging, integrated imaging solutions
GE Healthcare stands as a powerhouse in the radiopharmaceutical space, providing high-quality Fluorodeoxyglucose (FDG) tracers essential for PET scans used in oncology, cardiology, and neurology. Their comprehensive portfolio supports thousands of imaging centers globally, with a strong emphasis on seamless integration with advanced PET/CT systems for enhanced diagnostic accuracy.
Innovation Initiatives:
-
Advancing automated synthesis modules for FDG production
-
Collaborations with research institutions to improve tracer purity
-
Commitment to expanding access in emerging markets through training programs
Download FREE Sample Report: Fluorodeoxyglucose Market – View in Detailed Research Report
9️⃣ 2. Siemens Healthineers
Headquarters: Erlangen, Germany
Key Offering: 18F-FDG, PET scanner-compatible radiotracers
Siemens Healthineers operates across more than 70 countries, supplying FDG that powers over a million PET procedures annually. The company excels in delivering reliable, high-volume FDG production, helping healthcare providers meet the growing need for early disease detection amid rising chronic conditions.
Innovation Initiatives:
-
Investments in cyclotron technology for on-site FDG manufacturing
-
Partnerships with hospitals to optimize supply chain logistics
8️⃣ 3. Cardinal Health
Headquarters: Dublin, Ohio, USA
Key Offering: FDG radiopharmaceuticals, distribution services
Cardinal Health’s nuclear pharmacy division is a key supplier of FDG, leveraging an extensive network of facilities to ensure timely delivery to imaging centers. Their focus on quality control and regulatory adherence supports the safe use of FDG in diverse clinical applications, from cancer staging to therapy response assessment.
Innovation Initiatives:
-
Targets for increasing FDG yield through process optimization
-
Alliances with diagnostic labs to enhance tracer utilization
7️⃣ 4. Curium Pharma
Headquarters: Paris, France
Key Offering: 18F-FDG, specialized PET tracers
Curium Pharma is a prominent European player in radiopharmaceuticals, offering FDG that meets stringent EU standards for medical imaging. Serving civil and research sectors, the company invests heavily in advanced production methods like hot cell automation to boost efficiency and reduce costs.
Innovation Initiatives:
-
Aim to integrate 20% more automated systems by 2030
-
Launch of Europe’s advanced FDG facility in recent years
Download FREE Sample Report: Fluorodeoxyglucose Market – View in Detailed Research Report
6️⃣ 5. Lantheus Holdings
Headquarters: Bedford, Massachusetts, USA
Key Offering: FDG for diagnostic imaging, theranostics
Lantheus Holdings delivers FDG through a robust U.S.-based network, supporting over 500 imaging sites. Their offerings include carbon-neutral production options and advancements in tracer logistics to minimize decay time and maximize clinical value.
Innovation Initiatives:
-
Deployment of certified FDG at key North American centers
-
Goal of net-zero operations in radiopharma by mid-decade
5️⃣ 6. Jubilant Radiopharma
Headquarters: Montreal, Canada
Key Offering: High-purity 18F-FDG
Jubilant Radiopharma leads in North American FDG supply, providing proprietary tracers compatible with standard PET equipment. Their production scales efficiently to meet demands from major hospitals and research facilities across the continent.
Innovation Initiatives:
-
Annual output exceeding 500,000 doses
-
Expansion plans to double capacity by 2027
4️⃣ 7. Eckert & Ziegler
Headquarters: Berlin, Germany
Key Offering: FDG synthesis modules, radiotracers
Eckert & Ziegler serves more than 200 clients with FDG and related products, dominating in Central Europe and beyond. They play a crucial role in equipping labs with production tools, facilitating localized FDG manufacturing.
Innovation Initiatives:
-
Focus on compact synthesis for smaller facilities
-
Ongoing R&D in next-generation PET tracers
3️⃣ 8. Advanced Accelerator Applications (Novartis)
Headquarters: Saint-Genis-Pouilly, France
Key Offering: 18F-FDG, therapeutic radiopharma
Part of Novartis, Advanced Accelerator Applications is a top FDG provider in Asia-Pacific and Europe, distributing to over 150 centers. They’ve pioneered bio-based tracer enhancements, testing them in clinical trials for improved imaging resolution.
Innovation Initiatives:
-
Domestic R&D for tracer variants
-
Joint ventures to accelerate FDG adoption in developing regions
2️⃣ 9. NorthStar Medical Radioisotopes
Headquarters: Beloit, Wisconsin, USA
Key Offering: Non-uranium based FDG production
NorthStar Medical excels in sustainable FDG manufacturing in the U.S., converting facilities to produce cleaner tracers. Their innovative approach supports over 300 operators, focusing on reliable supply for oncology diagnostics.
Innovation Initiatives:
-
Plans for 1 million doses annually from renewable processes
-
Broadening distribution networks for faster delivery
1️⃣ 10. Elysia
Headquarters: Brussels, Belgium
Key Offering: Automated FDG production systems, 18F-FDG
Elysia specializes in turnkey solutions for FDG, aiding over 100 global sites in tracer production and logistics. As a leader in automation, they enable precise, high-volume output for PET imaging in clinical and research environments.
Innovation Initiatives:
-
Comprehensive automation for end-to-end tracer solutions
-
Collaborations with producers to refine synthesis protocols
Read Full Report: Fluorodeoxyglucose Market – View in Detailed Research Report
🌍 Outlook: The Future of Fluorodeoxyglucose Is More Precise and Accessible
The Fluorodeoxyglucose market is experiencing steady transformation. Although traditional production methods prevail, the sector is channeling significant resources into advanced synthesis technologies, quality assurance, and global distribution to meet escalating diagnostic needs.
📈 Key Trends Shaping the Market:
-
Expansion of PET facilities in North America, Europe, and Asia-Pacific
-
Regulatory advancements mandating higher tracer standards by 2030
-
Digital integration for production monitoring and dose tracking
-
Strategic alliances between pharma firms and imaging centers for innovation
Market Trends Affecting Fluorodeoxyglucose Production and Distribution
-
Integration of AI in synthesis processes — enhances yield prediction and quality control, streamlining operations for large-scale manufacturers. Recent tech infusions are redefining efficiency standards.
-
Shift to sustainable isotopes — companies are adopting non-uranium sources to comply with environmental regs and reduce supply risks. Examples include NorthStar’s pioneering methods.
-
Remote monitoring and telemedicine support — platforms for real-time tracer status and imaging data (from Siemens and GE) are vital for distributed healthcare networks.
-
Compact, modular production units — smaller, on-site synthesizers cut logistics costs and are ideal for rural or specialized clinics. Eckert & Ziegler leads this space.
-
Automation in quality assurance — robotic systems for purity testing and packaging minimize errors in high-volume environments, as seen in Elysia’s deployments.
Read Full Report: Fluorodeoxyglucose Market – View in Detailed Research Report
The companies listed above are not only powering diagnostic imaging—they’re leading the precision medicine revolution in healthcare.